/ CompletedNot ApplicableIIT Full-spectrum Medical Canabis Product (HemPhar) With a CBD:THC Ratio of 10:1 for Treatment of Spasticity in Children and Young Adults With Severe Forms of Cerebral Palsy
The proposed study is a double-blind, placebo-controlled, cross over study on 60 children aged 5 to 25 years with severe spasticity related to cerebral palsy (CP), level IV and V with full-spectrum medical cannabis product of CBD/THC ratio 10:1.
100 Clinical Results associated with PharmaHemp
0 Patents (Medical) associated with PharmaHemp
100 Deals associated with PharmaHemp
100 Translational Medicine associated with PharmaHemp